Incyte Corporation (INCY)
Incyte Announces Promising New Data on Oncology Candidate at ESMO
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma, expected by end of 2024. It is expected that the 7 major follicular lymphoma markets are expected to reach a value of $2.2 billion by 2034.
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL).
Incyte's blood cancer drug succeeds late-stage trial
Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.
FDA approves Incyte's treatment for chronic graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp's treatment for a type of graft-versus-host disease (GvHD).
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
On Tuesday, Incyte Corporation INCY reported second-quarter revenue of $1.04 billion, up from $954.6 million a year ago, beating the consensus of $1.03 billion.
Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Barry Flannelly - General Manager, North America Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Kripa Devarakonda - Truist Securities Paul Jeng - Guggenheim Partners Brian Abrahams - RBC Capital Markets Vikram Purohit - Morgan Stanley David Lebowitz - Citi Eric Schmidt - Cantor Fitzgerald James Shin - Deutsche Bank Jessica Fye - JPMorgan Chase Jay Olson - Oppenheimer & Company Evan Seigerman - BMO Capital Markets Reni Benjamin - Citizens JMP Andrew Berens - Leerink Partners Gavin Clark-Gartner - Evercore ISI Salveen Richter - Goldman Sachs Operator Hello, and welcome to the Incyte Second Quarter 2024 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago.
